Back to UBS Group AG UBS Group AG

LENZLENZ
Showing 8 of 10 quarters

Position history for UBS Group AGUBS Group AG's holdings in LENZ THERAPEUTICS INC

Yes. Ubs holds 111,825 shares of LENZ (Lenz Therapeutics), worth $635,166, as of its Q2 2026 13F filing. It reduced the position by 45,164 shares (-28.8%) from Q1 2026. Ubs has held LENZ in every 13F on record since Q1 2024, 10 quarterly filings.

Current Value

$635,166

Current Shares

111,825

Total Value Change

+$489,284

Total Shares Change

+105,680

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
111,825
-28.8%
$635,1660.0%$5.68
0
2026-Q1
Decreased
156,989
-90.0%
$1.4M0.0%$13.15
0
2025-Q4
Increased
1.6M
+30.8%
$25.1M0.0%$16.12
36
2025-Q3
Increased
1.2M
+36.3%
$56M0.0%$44.89
38
2025-Q2
Increased
881,481
+32.1%
$25.8M0.0%$30.18
37
2025-Q1
Increased
667,164
+676.4%
$17.2M0.0%$25.64
46
2024-Q4
Increased
85,928
+1298.3%
$2.5M0.0%$30.07
42
2024-Q3
Increased
6,145
+51.3%
$145,8820.0%$24.04
21

Other major holders of LENZ: RA CAPITAL MANAGEMENT, L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used